OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRCOpen, non-controlled, multicenter phase II study evaluating 5-FU/FA plus oxaliplatin (FOLFOX-4) plus cetuximab as first-line treatment for patients with undetectable EGFR-status in metastatic colorectal cancer. - OPERA

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 72

Inclusion Criteria

•Signed written informed consents
•Inpatient or outpatient =18 years of age
•Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum
•1st occurrence of metastatic disease (not curatively resectable)
•EGFR-negative tumour
•Life expectancy of at least 12 weeks
•Presence of at least 1 bi-dimensionally measurable index lesion (not in an irradiated area)
•ECOG performance status of = 2 at study entry
•Effective contraception for both male and female subjects if the risk of conception exists
•White blood cell count (WBC) = 3x109/L with neutrophils = 1.5x109/L, platelet count = 100x109/L, hemoglobin = 6.21 mmol/L (10 g/dL)
•ASAT and ALAT = 2.5 x upper reference range, or = 5 x upper reference range in case of liver metastasis
•Serum creatinine = 1.5 x upper reference range
•Recovery from relevant toxicity to previous treatment before study entry
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Previous exposure to epidermal growth factor receptor-targeting therapy
•Previous oxaliplatin-based chemotherapy
•Previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented > 6 months after end of adjuvant treatment
•Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug in the 30 days before inclusion.
•Concurrent chronic systemic immune therapy or hormone therapy not indicated in this study protocol except physiologic replacement
•Known hypersensitivity reaction to any of the components of study treatments
•Pregnancy (absence to be confirmed by ß-hCG test) or lactation period
•Brain metastasis and/or leptomeningeal disease (known or suspected)
•Clinically relevant coronary artery disease, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
•Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
•Previous malignancy other than colorectal cancer in the last 5 years except basal cell cancer of the skin or pre-invasive cancer of the cervix
•Known alcohol or drug abuse
•Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent
•Participation in another clinical study within the 30 days before registration.
•Significant disease which, in the investigator’s opinion, would exclude the subject from the study
•Peripheral neuropathy > grade 1
•Legal incapacity or limited legal capacity

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials